EMA
approval
· 2026-01-28
EMA Authorised: Jaypirca (pirtobrutinib) — Eli Lilly Nederland B.V.
Summary
The European Medicines Agency authorised Jaypirca (pirtobrutinib) for mantle cell lymphoma under conditional approval.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Lymphoma, Mantle-Cell. MAH: Eli Lilly Nederland B.V.. Decision date: 27/01/2026. Conditional approval